NEW YORK, July 18 - Bristol-Myers Squibb and Exelixis said Wednesday that they had signed a collaboration and licensing deal targeted at developing new cancer drugs.

Under the terms of the deal, Bristol-Myers Squibb of Princeton, NJ, will make an equity investment in Exelixis, which will use its knock-out technology to identify and validate targets that can trigger cell death in cancerous cells while leaving healthy cells unharmed. Bristol-Myers will then further analyze the targets in humans. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.